CClinicalTrials.gg
Not yet recruitingNCT07756684Updated Aug 11, 2026

Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer

An interventional study of Handheld cough device in Head and Neck Cancers, sponsored by Boston University Charles River Campus. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This preliminary study will examine the feasibility of a cough skill training treatment approach to rehabilitate voluntary cough function in people with head and neck cancer. Cough skill training focuses on practicing cough as a compensatory strategy for when food or liquid enters the airway. Primary outcomes will be feasibility and immediate treatment effects. The investigators hypothesize that the treatment will be feasible and will result in improvements to voluntary cough peak expiratory flow rate.

Read the detailed description

Participants will complete an initial in-person baseline evaluation of voluntary cough function, followed by five weekly telehealth treatment sessions for five weeks with home practice, before completing a post-treatment in-person evaluation. During each treatment session with study personnel and during home practice, they will complete 25 repetitions (5 sets of 5) of voluntary coughs.

02

Conditions studied

  • Head and Neck Cancers

Keywords

  • cough skill training
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Prior diagnosis of head and neck cancer at least 6 months post-diagnosis
  • Completed treatment for head and neck cancer, including surgery, radiation, or chemotherapy
  • Medically stable and able to follow commands and produce a voluntary cough
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Unable to provide informed consent assessed by a Montreal Cognitive Assessment (MoCA) score of \<20
  • Unable to follow study instructions
  • Unable to produce a voluntary cough
  • History of neurologic disease
  • Recent laryngeal surgery or vocal fold injury
  • Active respiratory infection or febrile illness within the past 14 days
  • Chronic, severe, or unstable respiratory disease
  • Asthma or bronchitis
  • Smoking within the past five years
  • Uncontrolled hypertension
  • Recent myocardial infarction, unstable angina, stroke, or hospitalization for heart failure within the past 6 months
  • Significant uncontrolled arrhythmia
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Cough skill training

    Participants will use a handheld cough device to produce voluntary coughs during 5 one hour treatment sessions.

    Device: Handheld cough device

Interventions

  • DeviceHandheld cough device

    During each treatment session with study personnel and during home practice, participants will complete 25 repetitions (5 sets of 5) of a voluntary coughs.

05

What researchers measure

Primary outcomes

  1. Feasibility of cough skill training

    Feasibility of cough skill training will be defined as the percentage of trials completing during treatment sessions.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in voluntary cough peak expiratory flow rate

    Peak expiratory flow rate is a measure of cough strength. Changes in cough strength from pretraining to post training will be recorded.

    Time frame: baseline, 6 weeks

  2. Acceptability assessed by the System Usability Scale

    The System Usability Scale (SUS) is a quick, 10-item questionnaire used to measure how people feel about the ease of use of a product, app, or website. Users reply using a 5-point scale from strongly disagree to strongly agree, resulting in an overall score from 0 to 100, with higher scores associated with greater acceptability.

    Time frame: 6 weeks

  3. Satisfaction assessed by the Beck Satisfaction Scale

    The 5-item satisfaction and acceptability scale used by Beck et al. (2017) measures treatment experience across five domains on a 5-point scale from 1=very unsatisfied to 5=very satisfied. It evaluates technology/tools, treatment tasks, convenience, organization/clinician interaction, and overall treatment satisfaction. Scores can range from 5 to 25 with higher scores associated with greater satisfaction.

    Time frame: 6 weeks

06

Study locations

1 site
  • Airway Protection Research Lab at Boston University
    Boston, Massachusetts 02215, United States
07

References and documents

Individual participant data

Plan to share: Yes — Deidentified analysis data will be stored in a public repository (Open Science Framework) upon publication. This data will only be used to reproduce the primary results of the study.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07756684
Lead sponsor
Boston University Charles River Campus
Responsible party
Sponsor
First posted
Aug 11, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

James Borders, PhD CCC-SLP
Contact
bordersj@bu.edu
617-353-3379
James Borders, PhD CCC-SLP
principal investigator · Boston University Charles River Campus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion